KWILP
SNDX icon

Kiwi Wealth Investments Limited Partnership’s Syndax Pharmaceuticals SNDX Stock Holding History

Kiwi Wealth Investments Limited Partnership’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31,586
Closed -$661K – 171
2023
Q2 		$661K Hold
31,586
– – 0.04% 176
2023
Q1 		$667K Hold
31,586
– – 0.04% 158
2022
Q4 		$804K Buy
+31,586
New +$737K 0.05% 168

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Kiwi Wealth Investments Limited Partnership's SNDX Position: Q3 2023 in Review

Kiwi Wealth Investments Limited Partnership sold out of Syndax Pharmaceuticals (SNDX) in Q3 2023, closing a stake of 31,586 shares — an estimated $661K sold.

Kiwi Wealth Investments Limited Partnership first reported a position in SNDX in Q4 2022 and held it in 3 quarters. The position peaked at $804K in Q4 2022. 175 funds tracked by Wall St. Rank hold SNDX as of Q3 2023.

  • Kiwi Wealth Investments Limited Partnership reported no remaining Syndax Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Kiwi Wealth Investments Limited Partnership sold 31,586 Syndax Pharmaceuticals shares in Q3 2023, an estimated $661K.
  • Kiwi Wealth Investments Limited Partnership first reported a position in Syndax Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Kiwi Wealth Investments Limited Partnership's Syndax Pharmaceuticals position peaked at $804K in Q4 2022.
  • 175 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2023.

Based on Kiwi Wealth Investments Limited Partnership's 13F filing for Q3 2023, filed 14 Nov 2023.